Compare · Research-Use-Only
Tsamorelin vs Ipamorelin
Tsamorelin is a GHRH analog (investigated for adipose-tissue compartment research) that stimulates the pituitary directly. Ipamorelin is a ghrelin-mimetic GH secretagogue producing a discrete GH pulse. Different upstream targets, overlapping downstream GH research-target effects.
Tsamorelin
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH, also known as somatocrinin) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, extending biological activity compared to native GHRH(1–44). Tesamorelin binds to and activates the GHRH receptor (GHRHR) on pituitary somatotrophs, stimulating pulsatile secretion of growth hormone (GH) through Gsα/adenylyl cyclase/cAMP/PKA signaling. GH in turn stimulates hepatic and peripheral production of IGF-1 (insulin-like growth factor 1), which mediates many anabolic and metabolic effects. Unlike exogenous GH administration, tesamorelin preserves pulsatile GH release and maintains feedback regulation through somatostatin, providing a more physiological GH profile. FDA approved tesamorelin (Egrifta®) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — the first GHRH analog approved in the US. Research interest extends to aging-related GH decline, cognition, and metabolic syndrome.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue pentapeptide that acts as a partial agonist at the ghrelin receptor (GHS-R1a), stimulating pulsatile GH release from pituitary somatotrophs. Unlike older GH secretagogues, ipamorelin demonstrates high selectivity with minimal effects on ACTH, cortisol, aldosterone, or prolactin.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →